Ilginatinib
- Generic Name
- Ilginatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20FN7
- CAS Number
- 1239358-86-1
- Unique Ingredient Identifier
- 56R994WX4L
- Background
NS-018 has been used in trials studying the treatment of Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, and Post-Essential Thrombocythemia Myelofibrosis.
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
Phase 2
Terminated
- Conditions
- Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
- Interventions
- Drug: Best Available Therapy
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04854096
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇩🇪Universitaetsklinikum Halle (Saale), Halle, Germany
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Phase 1
Completed
- Conditions
- Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01423851
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath